FDMTHealthcare · BiotechnologyThe 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. hold a median 12-month price target of $31 — +154.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 15 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores 4D Molecular Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on FDMT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +154.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | B. Riley Securities | Initiates | Buy | $37 |
| 20 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $36 |
| 30 Mar 2026 | Jefferies | Assumes | Buy | $40 → $21 |
| 20 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 28 Jan 2026 | Barclays | Initiates | Overweight | — |
| 18 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Nov 2025 | Barclays | Maintains | Overweight | — |
| 11 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 21 Oct 2025 | RBC Capital | Reiterates | Outperform | — |
| 12 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 12 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 1 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 3 July 2025 | Chardan Capital | Maintains | Buy | — |
| 9 May 2025 | Barclays | Maintains | Overweight | — |
| 9 May 2025 | Chardan Capital | Maintains | Buy | — |
| 9 May 2025 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FDMT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 18% of US stocks
Cheaper than 53% of US stocks
Cheaper than 71% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 4% of US stocks
Higher than 3% of US stocks
Higher than 23% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own 4D Molecular Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
4D Molecular Therapeutics granted 35,200 Restricted Stock Units to five new non-executive employees on August 11, 2026, under the company's 2025 Employment Inducement Award Plan.
Why it matters — The inducement grants signal the company is hiring and incentivizing new talent, which may be of interest to shareholders tracking team growth.
4D Molecular Therapeutics reported a Q2 loss of $1.04 per share, in line with the Zacks Consensus Estimate and compared to a loss of $0.98 per share a year ago. Revenue results topped analyst estimates.
Why it matters — FDMT watchers would track this quarterly earnings report to see how the company's financial results compare with analyst expectations and prior-year performance.
4D Molecular Therapeutics reported its Q2 2026 financial results and operational highlights, including completed enrollment in the 4D-150 4FRONT-2 wet AMD Phase 3 trial (topline data expected in H2 2027), topline 4FRONT-1 data expected in Q2 2027, positive two-year PRISM Phase 2b data, a planned DME Phase 3 initiation in Q3 2026, an Investor Day on October 21, 2026, a credit facility with Hercules Capital for up to $200 million, and $431 million in cash expected to fund operations into H2 2028.
Why it matters — The update outlines key near-term trial readouts and milestones plus a cash position expected to support operations through the second half of 2028, giving FDMT watchers a view of upcoming catalysts and financial runway.
Schaeffer's Research published an article titled "10 Stock Picks to Celebrate 45 Years of Schaeffer's" which was sent to Chart of the Week subscribers on Sunday, July 26. The article does not mention 4D Molecular Therapeutics by name.
Why it matters — FDMT watchers may care if the stock is among the ten picks highlighted, but the provided text does not confirm or deny its inclusion.
The 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. have a median 12-month price target of $31, with estimates ranging from $17 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering 4D Molecular Therapeutics, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 4D Molecular Therapeutics, Inc. 54 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, 4D Molecular Therapeutics, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +154.3% from the last close, and Ticker Nerd's factor model ranks 4D Molecular Therapeutics, Inc. 54 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering 4D Molecular Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FDMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $37 over the next 12 months.
4D Molecular Therapeutics, Inc. returned +71.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing genetic medicines for diseases in ophthalmology, pulmonology, and cardiology.
The most recent item we track (GlobeNewsWire, 14 Aug 2026): "4DMT Announces New Employment Inducement Grants". 4D Molecular Therapeutics granted 35,200 Restricted Stock Units to five new non-executive employees on August 11, 2026, under the company's 2025 Employment Inducement Award Plan.
4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing genetic medicines for diseases in ophthalmology, pulmonology, and cardiology. The company uses its proprietary Therapeutic Vector Evolution platform to design customized adeno-associated virus vectors that deliver therapeutic payloads to specific tissues through targeted routes of administration. Its current pipeline includes programs for wet age-related macular degeneration, diabetic macular edema, cystic fibrosis, Fabry disease cardiomyopathy, choroideremia, X-linked retinitis pigmentosa, geographic atrophy, and alpha-1 antitrypsin deficiency. 4D Molecular Therapeutics, Inc. concentrates on creating disease-targeted treatments that address both large-market and rare conditions, making it a notable participant in the evolving gene therapy landscape. The company is headquartered in Emeryville, California.
CEO Dr. David H. Kirn M.D. · 196 employees · United States · https://www.4dmoleculartherapeutics.com